Celsion’s R&D Improves After Split With Hisun
This article was originally published in PharmAsia News
Executive Summary
After Celsion and Zhejiang Hisun Pharmaceutical Co., Ltd.’s terminated their collaboration for cancer treatment ThermoDox in China due to failure to reach set clinical trial targets, the project, now belonging completely to Celsion’s, has observed three improvements.